CommercialCoverageMedium impact
Pelvic Congestion Syndrome Treatments (CPB 0441, reviewed 2026-07-09)
Aetna·Radiology, Vascular Surgery, OB-GYN +1 more·Medical Policy
Effective date
Jul 9, 2026
We identified it
Aug 13, 2026
Summary
Aetna's updated Clinical Policy Bulletin 0441 (effective 2026-07-09) establishes coverage criteria for pelvic congestion syndrome treatments, covering gonadal/ovarian vein embolization ONLY when patients have definitive diagnostic imaging (CT/MRI/venography) AND have failed appropriate pharmacotherapy. Median sacral vein embolization, sacral nerve neuromodulation, ovarian vein transposition, and micronized purified flavonoid fraction remain non-covered as experimental/investigational. Billing teams must verify both criteria are met before authorizing claims.
Action Required
Effective immediately (1 day old policy): Billing team must implement two-part coverage verification for all pelvic congestion syndrome claims billed under CPT 36245-36248, 37241, 75894, 75898 with ICD-10 N94.89. REQUIREMENT 1: Verify member has documented definitive diagnostic imaging (CT, MRI, or venography report in chart). REQUIREMENT 2: Verify member documentation shows failed trial of appropriate pharmacotherapy (analgesics, hormonal therapy) for at least 4-6 months prior to procedure. Update billing system to flag claims for manual review if either criterion is missing. DO NOT bill or authorize: CPT 64561, 64581, A4290 for sacral nerve modulation (non-covered); median sacral vein embolization (non-covered); ovarian vein transposition (no specific code); micronized purified flavonoid fraction (non-covered). CONSEQUENCES: Claims submitted without documented proof of both criteria will be denied by Aetna. Ensure providers complete encounter documentation template listing: (1) imaging type and date, (2) specific medications/hormone therapies trialed with dates. Route all questionable cases to clinical team for prior authorization review before submission.